Hormone-dependent malignancies represent a significant therapeutic challenge in modern oncology. Researchers constantly explore innovative small molecules that selectively disrupt key oncogenic and steroidogenic enzymes. Recently, investigators developed novel pyrrolo pyrimidine derivatives bearing azetidine functional groups to target hormone-sensitive breast cancer models. Specifically, this study examined the influence of methylsulfonyl, propylsulfonyl, and butylsulfonyl substitutions on antiproliferative efficacy and binding characteristics. The multidisciplinary workflow integrated computational absorption, distribution, metabolism, and excretion (ADME) screening with synthesis, structural characterization, and cell-based bioassays.

Structural Design of Pyrrolo Pyrimidine Derivatives

The heterocyclic pyrrolo[2,3-d]pyrimidine core serves as a versatile pharmacophore in medicinal chemistry. In this investigation, researchers incorporated an azetidine ring system to introduce structural rigidity and tune physicochemical properties. Furthermore, they methodically modified the sulfonyl side chains by attaching methyl, propyl, or butyl moieties. Consequently, these rational substitutions enabled the team to evaluate how alkyl chain length impacts spatial orientation and binding dynamics. Before chemical synthesis, virtual screening filtered out structures with poor drug-likeness. Therefore, only prioritized analogues underwent subsequent synthetic preparation. High-resolution spectroscopy subsequently confirmed the identity and purity of each synthesized compound. This targeted synthetic strategy provided a reliable chemical foundation to investigate whether these functionalized scaffolds could effectively inhibit tumor proliferation.

Computational Evaluation and 17β-HSD1 Binding Dynamics

The enzyme 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) plays a crucial role in converting low-potency estrone into potent estradiol within breast tumor tissue. Therefore, selective inhibition of 17β-HSD1 remains an attractive therapeutic strategy. In silico docking simulations against the 17β-HSD1 crystal structure (PDB: 3HB5) revealed that analogue BCD17 exhibited an outstanding docking profile. Specifically, BCD17 achieved a Glide docking score of -9.130 kcal/mol and a Glide energy of -69.236 kcal/mol. Additionally, molecular dynamics simulations confirmed that the ligand remained exceptionally stable within the catalytic cleft throughout the trajectory. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) calculations yielded a mean binding free energy of -109.49 ± 7.52 kcal/mol. Density functional theory (DFT) analysis also confirmed a well-balanced electronic distribution compatible with sustained target engagement.

In Vitro Antiproliferative and Pro-Apoptotic Effects

Following computational validation, investigators performed MTT cell viability assays against human MCF-7 breast carcinoma cells. The experimental evaluation confirmed concentration-dependent antiproliferative activity across the series. Specifically, the assays demonstrated half-maximal inhibitory concentration (IC50) values of 0.76 µM for BCD1, 0.75 µM for BCD9, and 1.83 µM for BCD17. Although BCD1 and BCD9 exhibited slightly lower IC50 values, the research team selected BCD17 as their primary candidate due to its superior computational stability and predicted safety characteristics. Subsequent cell-cycle analyses revealed that BCD17 induced significant cycle arrest. Furthermore, Annexin V/PI dual staining demonstrated robust pro-apoptotic activity in treated MCF-7 cells, confirming programmed cell death induction rather than nonspecific necrosis.

Selectivity Profile and Safety in Non-Malignant Cells

A critical consideration during early drug discovery is ensuring differential cytotoxicity between malignant and non-malignant tissues. Consequently, the researchers evaluated the cytotoxicity of these compounds against non-tumorigenic MCF-10A human mammary epithelial cells. Notably, both BCD9 and BCD17 demonstrated significantly lower cytotoxicity in MCF-10A cells when compared to the standard chemotherapeutic agent 5-fluorouracil (5-FU). This enhanced safety margin suggests that the azetidine-functionalized scaffold preserves healthy epithelial architecture more effectively than conventional antimetabolites. However, the authors noted that direct physical binding between BCD17 and 17β-HSD1 requires further experimental biophysical confirmation, such as surface plasmon resonance or enzyme inhibition kinetics.

Translational Significance for Oncology Therapeutics

Breast cancer remains the most diagnosed cancer among women worldwide, including in India where late-stage hormone receptor-positive presentations are frequent. While aromatase inhibitors and selective estrogen receptor modulators represent standard endocrine therapies, resistance mechanisms often emerge. Developing selective inhibitors against intracrine steroidogenic enzymes like 17β-HSD1 offers an alternative avenue to suppress local estradiol synthesis without completely ablating systemic estrogen production. The favorable safety profile, micromolar potency, and computational stability of BCD17 establish it as a promising lead candidate. Therefore, subsequent structural optimization may ultimately yield viable preclinical candidates for endocrine-resistant or estrogen-dependent breast malignancies.

Frequently Asked Questions

What is the therapeutic target of BCD17 in breast cancer?

Computational docking and molecular dynamics prioritize 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) as the potential enzymatic target for BCD17. This enzyme converts estrone into active estradiol within estrogen receptor-positive breast tissue. By computationally inhibiting 17β-HSD1, BCD17 aims to decrease intratumoral estrogen production, thereby attenuating estrogen-driven tumor proliferation in hormone-dependent breast cancer cells.

How does BCD17 compare with conventional agents like 5-fluorouracil?

In cytotoxicity assays using non-tumorigenic MCF-10A mammary epithelial cells, BCD17 demonstrated noticeably lower cellular toxicity than 5-fluorouracil (5-FU). This finding suggests a potentially superior preliminary therapeutic window. Standard chemotherapeutic agents frequently cause severe off-target cytotoxicity, whereas BCD17 showed targeted antiproliferative effects in MCF-7 cells while preserving non-malignant breast cells.

What future studies are necessary before clinical translation?

While in silico modeling and in vitro MTT assays yielded encouraging findings, direct enzymatic inhibition assays are necessary to validate 17β-HSD1 target engagement. Furthermore, researchers must conduct in vivo pharmacokinetic, bioavailability, and xenograft efficacy studies to determine metabolic stability, toxicity, and therapeutic dosing before advancing to clinical evaluations in humans.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

B V D et al. Design, synthesis, and preliminary antiproliferative evaluation of azetidine-functionalized pyrrolo[2,3-d]pyrimidines with integrated computational studies. J Biomol Struct Dyn. 2026 Aug 21. doi: 10.1080/07391102.2026.2717573. PMID: 42627359.

Day JM, Foster PA, Tutill HJ, Parsons MFC, Newman SP, et al. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer. 2008;122(9):1931-1940. doi: 10.1002/ijc.23358.

Laplante Y, Cadot C, Fournier MA, Poirier D. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Blocking of ER+ breast cancer cell proliferation induced by estrone. Bioorg Med Chem. 2008;16(4):1849-1860. doi: 10.1016/j.bmc.2007.11.018.